C0220825||Evaluation
C0031327||Pharmacokinetics
C0949647||Tocotrienols
C0086418||Humans
C0949647||Tocotrienols
C0856969||lower serum lipid parameters
C0856968||increase lipid parameters
C0218003||δ-Tocotrienol
C0949647||tocotrienols
C0007222||cardiovascular disease
C0087111||treatments
C0006826||cancer
C0032105||plasma
C0218003||δ-tocotrienol
C2349001||subjects
C1708492||increases in area under the curve
C0949647||tocotrienols
C0032105||plasma
C1705911||pharmacokinetic parameters
C0220825||evaluate
C0051928||annatto
C0949647||tocotrienols
C2349001||subjects
C0599549||tocols
C0949647||tocotrienols
C0087096||tocopherols
C0032105||plasmas
C2349001||subjects
C0936012||analyzed
C1705911||pharmacokinetic parameters
C1709323||open-label
C2986910||randomized study
C0031327||pharmacokinetics
C0218003||δ-tocotrienol
C2349001||subjects
C2349001||subjects
C0178913||Blood samples
C0217873||α-
C0217992||β-
C0206999||γ-
C0218003||δ-tocotrienols
C0087096||tocopherols
C0032105||plasmas
C0008562||HPLC
C0001563||Oral administration
C0949647||tocotrienols
C0032105||plasmas
C0218003||δ-tocotrienol isomer
C0032105||plasmas
C0218003||δ- tocotrienol isomer
C0449381||parameters
C0700287||reported
C0206999||γ-tocotrienol
C0217992||β- tocotrienol
C0217873||α-tocotrienol
C0304915||δ-tocopherol
C0017054||γ-tocopherol
C0005287||β-tocopherol
C0969677||α- tocopherol
C0031327||pharmacokinetics
C0218003||δ-tocotrienol
C0949647||tocotrienols
C0087096||tocopherols
C0969677||α-tocopherol
C0949647||tocotrienols
C0086418||humans
C0087111||treatments
C0006826||cancer
C0011847||diabetes
C0002395||Alzheimer's disease